{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Vision+Therapy&page=33",
    "query": {
      "intervention": "Vision Therapy",
      "page": 33
    },
    "page_size": 10
  },
  "pagination": {
    "page": 33,
    "page_size": 10,
    "total_count": 1706,
    "total_pages": 171,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Vision+Therapy&page=34&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Vision+Therapy&page=32&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-29T01:24:32.788Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00354419",
      "title": "Cyclophosphamide, Antithymocyte Globulin, and Total-Body Irradiation in Treating Patients With Severe Aplastic Anemia Undergoing Umbilical Cord Blood Transplant",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Aplastic Anemia"
      ],
      "interventions": [
        {
          "name": "total-body irradiation",
          "type": "RADIATION"
        },
        {
          "name": "cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "anti-thymocyte globulin",
          "type": "BIOLOGICAL"
        },
        {
          "name": "cyclosporine",
          "type": "DRUG"
        },
        {
          "name": "umbilical cord blood transplantation",
          "type": "PROCEDURE"
        },
        {
          "name": "mycophenolate mofetil",
          "type": "DRUG"
        },
        {
          "name": "bone marrow aspiration",
          "type": "PROCEDURE"
        },
        {
          "name": "DNA analysis",
          "type": "GENETIC"
        },
        {
          "name": "filgrastim",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "RADIATION",
        "DRUG",
        "BIOLOGICAL",
        "PROCEDURE",
        "GENETIC"
      ],
      "sponsor": "Fred Hutchinson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "40 Years",
        "sex": "ALL",
        "summary": "Up to 40 Years"
      },
      "enrollment_count": 30,
      "start_date": "2006-02",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2011-01-05",
      "last_synced_at": "2026-10-29T01:24:32.788Z",
      "location_count": 1,
      "location_summary": "Seattle, Washington",
      "locations": [
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00354419"
    },
    {
      "nct_id": "NCT02304458",
      "title": "Nivolumab With or Without Ipilimumab in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Sarcomas",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Metastatic Melanoma",
        "Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor",
        "Recurrent Hodgkin Lymphoma",
        "Recurrent Malignant Solid Neoplasm",
        "Recurrent Melanoma",
        "Recurrent Neuroblastoma",
        "Recurrent Non-Hodgkin Lymphoma",
        "Recurrent Osteosarcoma",
        "Recurrent Rhabdomyosarcoma",
        "Refractory Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor",
        "Refractory Hodgkin Lymphoma",
        "Refractory Malignant Solid Neoplasm",
        "Refractory Melanoma",
        "Refractory Neuroblastoma",
        "Refractory Non-Hodgkin Lymphoma",
        "Refractory Osteosarcoma",
        "Refractory Rhabdomyosarcoma",
        "Stage III Cutaneous Melanoma AJCC v7",
        "Stage IIIA Cutaneous Melanoma AJCC v7",
        "Stage IIIB Cutaneous Melanoma AJCC v7",
        "Stage IIIC Cutaneous Melanoma AJCC v7",
        "Stage IV Cutaneous Melanoma AJCC v6 and v7",
        "Unresectable Melanoma"
      ],
      "interventions": [
        {
          "name": "Ipilimumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Nivolumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Pharmacological Study",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Months",
        "maximum_age": "30 Years",
        "sex": "ALL",
        "summary": "12 Months to 30 Years"
      },
      "enrollment_count": 140,
      "start_date": "2015-03-30",
      "completion_date": "2023-03-31",
      "has_results": true,
      "last_update_posted_date": "2023-10-17",
      "last_synced_at": "2026-10-29T01:24:32.788Z",
      "location_count": 24,
      "location_summary": "Birmingham, Alabama • Los Angeles, California • Orange, California + 21 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02304458"
    },
    {
      "nct_id": "NCT00333255",
      "title": "Nepafenac Opthalmic Suspension 0.1% Compared to Acular LS for Treatment of Inflammation After Cataract Surgery",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Cataract"
      ],
      "interventions": [
        {
          "name": "Nepafenac Ophthalmic Suspension, 0.1%",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Alcon Research",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "10 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "10 Years and older"
      },
      "enrollment_count": 267,
      "start_date": "2005-09",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2009-07-08",
      "last_synced_at": "2026-10-29T01:24:32.788Z",
      "location_count": 1,
      "location_summary": "Nacogdoches, Texas",
      "locations": [
        {
          "city": "Nacogdoches",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00333255"
    },
    {
      "nct_id": "NCT05287204",
      "title": "Critical Illness Myopathy and Trajectory of Recovery in AKI Requiring CRRT",
      "overall_status": "UNKNOWN",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Acute Kidney Injury",
        "Critical Illness Myopathy",
        "Dialysis; Complications"
      ],
      "interventions": [
        {
          "name": "Musculoskeletal ultrasound",
          "type": "DIAGNOSTIC_TEST"
        },
        {
          "name": "Assessments of muscle strength and physical function",
          "type": "DIAGNOSTIC_TEST"
        },
        {
          "name": "Metabolomics",
          "type": "DIAGNOSTIC_TEST"
        }
      ],
      "intervention_types": [
        "DIAGNOSTIC_TEST"
      ],
      "sponsor": "University of Iowa",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "89 Years",
        "sex": "ALL",
        "summary": "18 Years to 89 Years"
      },
      "enrollment_count": 10,
      "start_date": "2021-11-29",
      "completion_date": "2024-12-30",
      "has_results": false,
      "last_update_posted_date": "2024-03-28",
      "last_synced_at": "2026-10-29T01:24:32.788Z",
      "location_count": 3,
      "location_summary": "Iowa City, Iowa • Lexington, Kentucky • Albuquerque, New Mexico",
      "locations": [
        {
          "city": "Iowa City",
          "state": "Iowa"
        },
        {
          "city": "Lexington",
          "state": "Kentucky"
        },
        {
          "city": "Albuquerque",
          "state": "New Mexico"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05287204"
    },
    {
      "nct_id": "NCT05431543",
      "title": "Evaluation of the Safety and Effectiveness of Aceclidine (LNZ101) and Aceclidine + Brimonidine (LNZ100) in the Treatment of Presbyopia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Presbyopia",
        "Refractive Errors",
        "Eye Diseases"
      ],
      "interventions": [
        {
          "name": "Aceclidine+Brimonidine combination ophthalmic solution",
          "type": "DRUG"
        },
        {
          "name": "Aceclidine ophthalmic solution",
          "type": "DRUG"
        },
        {
          "name": "Vehicle proprietary ophthalmic solution",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "LENZ Therapeutics, Inc",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "45 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "45 Years to 75 Years"
      },
      "enrollment_count": 59,
      "start_date": "2022-08-06",
      "completion_date": "2022-12-14",
      "has_results": true,
      "last_update_posted_date": "2024-09-05",
      "last_synced_at": "2026-10-29T01:24:32.788Z",
      "location_count": 5,
      "location_summary": "Chandler, Arizona • Glendale, California • Andover, Massachusetts + 2 more",
      "locations": [
        {
          "city": "Chandler",
          "state": "Arizona"
        },
        {
          "city": "Glendale",
          "state": "California"
        },
        {
          "city": "Andover",
          "state": "Massachusetts"
        },
        {
          "city": "Memphis",
          "state": "Tennessee"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05431543"
    },
    {
      "nct_id": "NCT07025811",
      "title": "A Study to Explore Signs, Symptoms, and Biomarkers in Dry Eye Disease Participants Following Anti-inflammatory Treatment",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Dry Eye Disease"
      ],
      "interventions": [
        {
          "name": "Vevye®",
          "type": "DRUG"
        },
        {
          "name": "Xiidra®",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Hoffmann-La Roche",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 378,
      "start_date": "2025-07-09",
      "completion_date": "2026-07-16",
      "has_results": false,
      "last_update_posted_date": "2026-07-27",
      "last_synced_at": "2026-10-29T01:24:32.788Z",
      "location_count": 8,
      "location_summary": "Newport Beach, California • Louisville, Kentucky • Andover, Massachusetts + 5 more",
      "locations": [
        {
          "city": "Newport Beach",
          "state": "California"
        },
        {
          "city": "Louisville",
          "state": "Kentucky"
        },
        {
          "city": "Andover",
          "state": "Massachusetts"
        },
        {
          "city": "Garner",
          "state": "North Carolina"
        },
        {
          "city": "Shelby",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07025811"
    },
    {
      "nct_id": "NCT04522336",
      "title": "Pembrolizumab and Chemoradiotherapy for the Treatment of Unresectable Gastroesophageal Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8",
        "Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8",
        "Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8",
        "Clinical Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8",
        "Localized Gastroesophageal Junction Adenocarcinoma",
        "Locally Advanced Gastroesophageal Junction Adenocarcinoma",
        "Pathologic Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8",
        "Pathologic Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8",
        "Pathologic Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8",
        "Pathologic Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8",
        "Pathologic Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8",
        "Pathologic Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8",
        "Postneoadjuvant Therapy Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8",
        "Postneoadjuvant Therapy Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8",
        "Postneoadjuvant Therapy Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8",
        "Postneoadjuvant Therapy Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8",
        "Postneoadjuvant Therapy Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8",
        "Postneoadjuvant Therapy Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8",
        "Unresectable Gastroesophageal Junction Adenocarcinoma"
      ],
      "interventions": [
        {
          "name": "Docetaxel",
          "type": "DRUG"
        },
        {
          "name": "Fluorouracil",
          "type": "DRUG"
        },
        {
          "name": "Oxaliplatin",
          "type": "DRUG"
        },
        {
          "name": "Pembrolizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Radiation Therapy",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL",
        "RADIATION"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 16,
      "start_date": "2020-09-16",
      "completion_date": "2026-08-07",
      "has_results": false,
      "last_update_posted_date": "2026-08-13",
      "last_synced_at": "2026-10-29T01:24:32.788Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04522336"
    },
    {
      "nct_id": "NCT00931801",
      "title": "BATAR: Individuals Currently Taking Boosted Atazanavir as Part of an HIV Treatment Regimen Will be Evaluated to See if Substituting Raltegravir for Nucleoside Transcriptase Inhibitors Will be Safe and Well Tolerated.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "HIV"
      ],
      "interventions": [
        {
          "name": "atazanavir/raltegravir",
          "type": "DRUG"
        },
        {
          "name": "atazanavir/tenofovir/emtricitabine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Community Research Initiative of New England",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 43,
      "start_date": "2009-12",
      "completion_date": "2012-03",
      "has_results": true,
      "last_update_posted_date": "2017-07-21",
      "last_synced_at": "2026-10-29T01:24:32.788Z",
      "location_count": 9,
      "location_summary": "Phoenix, Arizona • Los Angeles, California • Denver, Colorado + 6 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00931801"
    },
    {
      "nct_id": "NCT00675207",
      "title": "Comparison of Brimonidine Purite, Dorzolamide, and Brinzolamide as Adjunctive Therapy to Prostaglandin Analogs",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Primary Open Angle Glaucoma",
        "Ocular Hypertension"
      ],
      "interventions": [
        {
          "name": "Brimonidine purite 0.15%",
          "type": "DRUG"
        },
        {
          "name": "Dorzolamide 2%",
          "type": "DRUG"
        },
        {
          "name": "Brinzolamide 1%",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Northwestern Ophthalmic Institute S.C.",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "41 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "41 Years and older"
      },
      "enrollment_count": 120,
      "start_date": "2006-01",
      "completion_date": "2007-07",
      "has_results": false,
      "last_update_posted_date": "2008-05-08",
      "last_synced_at": "2026-10-29T01:24:32.788Z",
      "location_count": 1,
      "location_summary": "Glenview, Illinois",
      "locations": [
        {
          "city": "Glenview",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00675207"
    },
    {
      "nct_id": "NCT04382625",
      "title": "Hydroxychloroquine in SARS-CoV-2 (COVID-19) Pneumonia Trial",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "SARS-CoV-2 Pneumonia",
        "COVID-19"
      ],
      "interventions": [
        {
          "name": "Hydroxychloroquine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Kootenai Health",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2020-10",
      "completion_date": "2022-06-01",
      "has_results": false,
      "last_update_posted_date": "2021-02-05",
      "last_synced_at": "2026-10-29T01:24:32.788Z",
      "location_count": 1,
      "location_summary": "Coeur d'Alene, Idaho",
      "locations": [
        {
          "city": "Coeur d'Alene",
          "state": "Idaho"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04382625"
    }
  ]
}